RARA
- Known as:
- RARA
- Catalog number:
- Y213425
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- RARA
Related genes to: RARA
- Gene:
- RARA NIH gene
- Name:
- retinoic acid receptor alpha
- Previous symbol:
- -
- Synonyms:
- RAR, NR1B1
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-09
- Date modifiied:
- 2019-04-23
Related products to: RARA
Related articles to: RARA
- Collagenous gastritis is a rare pediatric disease characterized by chronic gastritis with superficial, irregular mucosal involvement, focal atrophy of the gastric glands, an inflammatory infiltrate predominantly composed of lymphocytes and plasma cells, and areas of epithelial erosion. Focal collagen deposition in the subepithelial region of the lamina propria is a hallmark feature. Gastric epithelial erosions can cause hematemesis and, more generally, occult gastrointestinal bleeding, leading to chronic iron-deficiency anemia. Currently, there are no established management guidelines, and data on long-term follow-up are lacking. We report a clinical case of collagenous gastritis, emphasizing its features and therapeutic approach. - Source: PubMed
Ruzza AriannaAccomando FrancescoCostantini MatteoValletta Enrico - Not available. - Source: PubMed
Publication date: 2026/05/07
Su ZhanFeng Xianqi - In-hospital mortality remains a significant concern in infant cardiac surgery, yet precise risk stratification tools are lacking. The prognostic value of the red cell distribution width-to-albumin ratio (RAR)-a composite marker of inflammation and nutritional status-remains unestablished in this population. This study aimed to examine the association between RAR and in-hospital mortality in infants undergoing cardiac surgery. - Source: PubMed
Publication date: 2026/04/16
Yang QiLiu QiZhong XingLuo DandongZhang Chongjian - Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia defined by the t(15;17)(q24;q21)-derived fusion. However, a small subset of patients harbor cryptic or atypical rearrangements that escape detection by routine real-time quantitative RT-PCR (qRT-PCR). We report a 34-year-old man presenting typical APL in whom repeated testing for the canonical long, short, and variant transcripts yielded negative results. RNA sequencing subsequently identified a previously unreported in-frame fusion linking exon 8 to a 58-base pair-deleted exon 3. The resulting chimeric transcript retained the coiled-coil domain as well as the DNA- and ligand-binding domains of , suggesting preserved sensitivity to retinoid-based therapy. Consistent with this prediction, induction therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) resulted in achievement of complete molecular remission. Molecular relapse occurred three months after premature discontinuation of maintenance therapy, underscoring the leukemogenic potential of this novel fusion. This observation expands the molecular spectrum of APL and highlights the potential value of incorporating RNA sequencing into the diagnostic workflow for morphologically suspected but PCR-negative APL. - Source: PubMed
Publication date: 2026/04/14
Chen Jia-PingHou Jun-JieChen Xiao-YongCao Yi-XuanKe PengZhou Ji-HaoHu Li-Na - Acute promyelocytic leukemia (APML) is characterized by promyelocytic leukemia retinoic acid receptor alpha (PML-RARA) fusion gene resulting from at (15;17) translocation. The purpose of this study was to evaluate the clinical outcomes of patients with APML treated with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), as well as to assess the diagnostic utility of flow cytometry (FCM) in this setting.This retrospective study was conducted from April 2021 to March 2024. Patients of either sex, aged 10 to 67 years, with APML were included in study. Patient history, symptom progression and lab parameters such as hemoglobin (Hb), total leucocytes count (TLC), and platelets count were extracted from medical records. A total of 45 patients with median age 33 years, with majority of female (55.6%) were included in study. The PML-RARA isoforms were detected in 97.8% patients, positive trait for bcr type 1 observed in 47.7% patients. Majority of patients (57.8%) were low risk type of APML. Most of patients show positive immunophenotype for CD117 (100%), CD33 (100%), MPO (94.7%), CD13 (97.7%) and CD64 (89.5%). Post treatment, complete remission was observed in 90% patients. The Hb levels significantly increased from baseline to last follow-up (7.7g/dL vs. 13.6 g/dL; < .0001). Similarly, platelet count significantly increased from baseline to last follow-up (0.3 × 109/L vs. 2.6 × 109/L; < 0.001). While, TLC significantly decreased from baseline in high risk cases to last follow-up (24 × 109/L vs. 9 × 109/L; = 0.016). Patients with APML can be successfully treated with a combination of ATO and ATRA. - Source: PubMed
Publication date: 2025/06/23
Kamat GirishBalikai GirishGoni DeepakPattar Utkarsh